The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

CancerCare announces co-payment assistance for pancreatic cancer patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CANCERCARE announced the availability of co-payment assistance for pancreatic cancer patients through the CancerCare Co-Payment Assistance Foundation.

People receiving assistance from CCAF also have access to the full array of CancerCare services, including counseling, support groups, resource referrals, publications, education and financial assistance with treatment-related expenses such as transportation and child care.

“We are thrilled to provide this crucial co-payment assistance to people coping with a pancreatic cancer diagnosis,” said Patricia Goldsmith, CEO of CancerCare. “Pancreatic cancer can be an especially challenging diagnosis to treat, and the CancerCare Co-Payment Assistance Foundation is committed to easing the financial burden so that patients can focus on managing their diagnosis and maintaining quality of life during treatment.”

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalRegulatory NewsTrials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
By Edison T. Liu
Sponsored

Why both somatic and germline genomic profiling are essential for precision oncology

Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 
By Heather Hampel and David W. Craig
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account